DALK Corneal Transplant
Understanding DALK: A Modern Approach to Corneal Transplants
DALK focuses on treating diseases that affect the front portion of the cornea while preserving healthy inner tissue. The technique offers important advantages over full-thickness transplants.
DALK replaces the diseased stroma and epithelium while leaving the patient’s own Descemet’s membrane and endothelium in place. This difference reduces the chance of immune rejection and promotes long-term corneal clarity.
Because the endothelium remains untouched, the cornea maintains its natural ability to stay clear and hydrated. Patients often need less intense immunosuppression and enjoy a safer overall recovery.
By removing scarred or misshapen tissue and replacing it with a smooth donor layer, DALK allows light to focus properly on the retina. This can restore sharp, comfortable vision for people with keratoconus or corneal scarring.
Who Is a Good Candidate for DALK?
DALK is intended for patients whose corneal disease is limited to the outer layers, leaving the endothelium healthy. Several corneal conditions meet these criteria.
The procedure is commonly recommended for the following problems:
- Keratoconus that thins and distorts the cornea
- Corneal scars from trauma, infection, or surgery
- Superficial corneal dystrophies such as granular or lattice dystrophy
- Chemical or thermal burns confined to the outer cornea
- Refractive surgery complications like post-LASIK ectasia
Because the surgery spares the endothelium, younger patients face a much lower lifetime risk of rejection and typically require fewer steroid drops over the years. The graft can last for decades without the risk of endothelial cell failure.
Patients with endothelial disorders such as Fuchs’ Dystrophy or pseudophakic bullous keratopathy need a transplant that replaces the inner layer, such as DSEK or DMEK. Deep scars involving Descemet’s membrane may also prevent successful DALK, making a full-thickness transplant necessary.
Clinical Evidence Supporting the Effectiveness of DALK
Recent studies comparing DALK with penetrating keratoplasty highlight the safety and success of this partial-thickness approach.
Research from 2023 shows that DALK can reduce graft rejection rates to under 20 percent, compared with over 30 percent for full-thickness transplants. Both procedures offer similar graft survival, but DALK patients experience fewer serious immune complications.
Multiple investigations confirm that DALK delivers excellent visual outcomes with a lower risk profile. These advantages make it a strong option for diseases that spare the endothelium.
The Key Benefits of DALK
Patients and surgeons value DALK for a variety of clinical and practical reasons.
Keeping healthy endothelial cells intact supports long-term corneal clarity and graft survival.
Because the immune system does not attack donor endothelium, rejection rates are markedly lower than with full-thickness grafts.
Many people regain functional vision sooner, helping them return to work and daily tasks more quickly.
DALK can use corneal tissue that might not qualify for penetrating keratoplasty, broadening the donor pool.
The eye remains a closed system during surgery, which lessens intraoperative risks and produces a stronger globe afterward.
Because success depends on the patient’s own endothelium, long-term survival rates are high and the need for repeat surgery is reduced.
Lower rejection risk allows for shorter and less intensive steroid regimens, minimizing the chance of glaucoma or cataracts.
Frequently Asked Questions
These answers address the most common concerns about DALK surgery and recovery.
Yes. By replacing cloudy or misshapen tissue with a clear donor layer, DALK often delivers significant visual improvement.
No. The procedure is usually performed on an outpatient basis, and most patients go home the same day.
While younger individuals make up the majority of cases, older patients with a healthy endothelium can also benefit from DALK.
Yes. The surgery is effective for scars limited to the outer corneal layers, restoring clarity and shape.
Because your own endothelium remains intact, the graft can last for decades, and many patients enjoy lifelong results.
The surgery is performed under anesthesia, so you should not feel pain. Mild irritation or light sensitivity after surgery is normal and usually short-lived.
Most patients will need glasses or specialized contact lenses to achieve their best vision once healing is complete.
DALK is technically challenging and requires specialized training. In addition, early treatments such as corneal cross-linking mean fewer patients progress to needing a transplant, reducing opportunities for surgeons to refine this skill.
Your Next Step to Clearer Vision
If you have corneal disease and want to explore whether DALK is right for you, reach out to our team for a comprehensive evaluation. We have served families across North Jersey and the greater New York City area for nearly five decades and look forward to guiding you toward healthier, sharper vision.
excellent surgeon . very satisfied with cornea transplant.
Greg
Patient at Westwood Ophthalmology for almost 10 years. Dr. Pagan is my ophthalmologist, she is wonderful. I saw Dr. Lee recently for cornea surgery and follow-up. He is competent and caring.
Beth Cruz
They did a very thorough analysis and found I had a scratched cornea. This will be my new go to for optometry.
Paula Clark
Dr Glen Bianchi successfully fixed my double vision!! I can see normal again !!!! I've had a double vision as an adult for the past 17 years and it's been debilitating for me.
Bob C
We switched to Dr. Bianchi after an unpleasant pediatric ophthalmologist. Our experience with Dr. Bianchi and Westwood Ophthalmology was wonderful! Everyone put us at ease, trusted expertise.
Lara A